Unicycive Therapeutics (UNCY) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

UNCY Unicycive Therapeutics

Watchlist

0.6779
+0.0878+14.88%

Close Nov 27 16:00 ET

0.6900
+0.0121+1.78%

Post 20:01 ET

70.36MMarket Cap-1473P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
Yahoo Finance06:57 ET
Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark
Dow JonesNov 22 09:49 ET · Ratings
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 21 07:00 ET
Maxim Group Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Announces Target Price $2
Moomoo NewsNov 14 12:32 ET · Ratings
Express News | Unicycive Therapeutics Inc Files for Mixed Shelf of up to $100 Mln - SEC Filing
ReutersNov 13 17:30 ET
Unicycive Therapeutics | 8-K: Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
SECNov 13 08:07 ET

Comments

Dangerdog

Yesterday 07:09

$Unicycive Therapeutics (UNCY.US)$ Is this starting to come alive?

AdrianHHA

Nov 14 05:32

$Unicycive Therapeutics (UNCY.US)$
H.C. Wainwright raised the firm’s on Unicycive Therapeutics () to $4 from $2.50 and keeps a Buy rating on the shares following the Q3 report.
Published first on – the ultimate source for real-time, market-moving breaking financ

Jaguar8

Nov 13 06:16

NEWS ER

$Unicycive Therapeutics (UNCY.US)$
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Positive
FDA acceptance of OLC New Drug Application with PDUFA date set for June 28, 2025
Strong patient preference for OLC: 79% preferred it over prior therapy
Successful completion of UNI-494 Phase 1 trial with positive safety profile
Patent granted for UNI-494 valid until 2040
Cash runway extended into 2026 with $32.3M cash position
Reduced net loss to $4.1M from $4.4...

Jaguar8

Nov 11 06:03

NEWS

$Unicycive Therapeutics (UNCY.US)$
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Unicycive Therapeutics announced FDA acceptance of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for treating hyperphosphatemia in chronic kidney disease patients on dialysis. The FDA set a PDUFA target date of June 28, 2025. OLC aim...